Evolus Inc Stock Chance of Future Stock Price Finishing Under 11.08
| EOLS Stock | USD 14.74 0.30 1.99% |
Closest to current price Evolus long PUT Option Payoff at Expiration
Evolus |
Evolus Target Price Odds to finish below 11.08
The tendency of Evolus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 11.08 or more in 90 days |
| 14.74 | 90 days | 11.08 | about 17.57 |
Based on a normal probability distribution, the odds of Evolus to drop to $ 11.08 or more in 90 days from now is about 17.57 (This Evolus Inc probability density function shows the probability of Evolus Stock to fall within a particular range of prices over 90 days) . Probability of Evolus Inc price to stay between $ 11.08 and its current price of $14.74 at the end of the 90-day period is about 77.75 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.13 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Evolus will likely underperform. Additionally Evolus Inc has an alpha of 0.2009, implying that it can generate a 0.2 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Evolus Price Density |
| Price |
Predictive Modules for Evolus
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Evolus Inc. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Evolus Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Evolus is not an exception. The market had few large corrections towards the Evolus' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Evolus Inc, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Evolus within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.20 | |
β | Beta against Dow Jones | 2.13 | |
σ | Overall volatility | 1.40 | |
Ir | Information ratio | 0.04 |
Evolus Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Evolus for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Evolus Inc can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Evolus Inc had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 202.09 M. Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 173.69 M. | |
| Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels |
Evolus Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Evolus Stock often depends not only on the future outlook of the current and potential Evolus' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Evolus' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 56.9 M | |
| Cash And Short Term Investments | 62.8 M |
Evolus Technical Analysis
Evolus' future price can be derived by breaking down and analyzing its technical indicators over time. Evolus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Evolus Inc. In general, you should focus on analyzing Evolus Stock price patterns and their correlations with different microeconomic environments and drivers.
Evolus Predictive Forecast Models
Evolus' time-series forecasting models is one of many Evolus' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Evolus' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Evolus Inc
Checking the ongoing alerts about Evolus for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Evolus Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Evolus Inc had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 202.09 M. Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 173.69 M. | |
| Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels |
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.